Evidence map›Paper›PMID 23913966›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2013

Shaping the murine macrophage phenotype: IL-4 and cyclic AMP synergistically activate the arginase I promoter.

Kathryn E Sheldon, Harish Shandilya, Diane Kepka-Lenhart, Mirjana Poljakovic, Arundhati Ghosh, Sidney M Morris

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 67 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Selective phosphodiesterase 4 inhibitor roflumilast reduces inflammation and lung injury in models of betacoronavirus infection in mice.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Modulation of IL-4/IL-13 cytokine signaling in the context of allergic disease.The Journal of allergy and clinical immunology · 2022
    Review
  10. Taurodeoxycholic acid and valine reverse obesity-associated augmented alloimmune responses and prolong allograft survival.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022
    Article
  11. Review
  12. Review
  13. Evidence for reprogramming of monocytes into reparative alveolar macrophages in vivo by targeting PDE4b.American journal of physiology. Lung cellular and molecular physiology · 2021
    Article
  14. Deficiency in ST2 signaling ameliorates RSV-associated pulmonary hypertension.American journal of physiology. Heart and circulatory physiology · 2021
    Article
  15. The Role of Macrophages in the Host's Defense againstPathogens (Basel, Switzerland) · 2021
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kathryn E SheldonDepartment of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219, USA.
Harish Shandilya
Diane Kepka-Lenhart
Mirjana Poljakovic
Arundhati Ghosh
Sidney M Morris
University of Pittsburgh · USUPMC Hillman Cancer Center · US

Funding

Role of Arginase in Inflammation and TraumaR01GM057384 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MORRIS, SIDNEY MACHEN · 1998 to 2012
$3.8M
GENOME STABILITY IN RAD MUTANTSR01GM057484 · NIGMS · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI BAILIS, ADAM M · 1998 to 2006
$2.0M
NIGMS NIH HHS GM057484NIGMS NIH HHS R01 GM057384NIGMS NIH HHS R01 GM057484
6 · The paper itself

Abstract

Arginase I is a marker of murine M2 macrophages and is highly expressed in many inflammatory diseases. The basis for high arginase I expression in macrophages in vivo is incompletely understood but likely reflects integrated responses to combinations of stimuli. Our objective was to elucidate mechanisms involved in modulating arginase I induction by IL-4, the prototypical activator of M2 macrophages. IL-4 and 8-bromo-cAMP individually induce arginase I, but together they rapidly and synergistically induce arginase I mRNA, protein, and promoter activity in murine macrophage cells. Arginase I induction by IL-4 requires binding of the transcription factors STAT6 and C/EBPβ to the IL-4 response element of the arginase I gene. Chromatin immunoprecipitation showed that the synergistic response involves binding of both transcription factors to the IL-4 response element at levels significantly greater than in response to IL-4 alone. The results suggest that C/EBPβ is a limiting factor for the level of STAT6 bound to the IL-4 response element. The enhanced binding in the synergistic response was not due to increased expression of either STAT6 or C/EBPβ but was correlated primarily with increased nuclear abundance of C/EBPβ. Our findings also suggest that induction of arginase I expression is stochastic; that is, differences in induction reflect differences in probability of transcriptional activation and not simply differences in rate of transcription. Results of the present study also may be useful for understanding mechanisms underlying regulated expression of other genes in macrophages and other myeloid-derived cells in health and disease.

Indexed as

Promoter Regions, GeneticAnimalsArginaseCell LineChromatin ImmunoprecipitationCyclic AMPGene Expression RegulationImmunoblottingInterleukin-4Macrophage ActivationMacrophagesMicePhenotypePolymerase Chain ReactionTransfectionArg1 protein, mouseArginaseCyclic AMPInterleukin-4

Identifiers

PMID23913966
PMCPMC3829606
OpenAlexW2169735431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.